11846 related articles for article (PubMed ID: 1295447)
1. The cytoskeleton as a subcellular target of the antineoplastic drug lonidamine.
Malorni W; Meschini S; Matarrese P; Arancia G
Anticancer Res; 1992; 12(6B):2037-45. PubMed ID: 1295447
[TBL] [Abstract][Full Text] [Related]
2. 3-Aminobenzamide induces cytoskeleton rearrangement in M14 melanoma cells.
Malorni W; Rainaldi G; Straface E; Rivabene R; Cossarizza A; Capri M; Monti D; Franceschi C
Biochem Biophys Res Commun; 1994 Jul; 202(2):915-22. PubMed ID: 8048965
[TBL] [Abstract][Full Text] [Related]
3. Membrane and cytoskeleton are intracellular targets of rhein in A431 cells.
Iosi F; Santini MT; Malorni W
Anticancer Res; 1993; 13(2):545-54. PubMed ID: 8390805
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive real-time monitoring of intracellular cancer cell metabolism and response to lonidamine treatment using diffusion weighted proton magnetic resonance spectroscopy.
Mardor Y; Kaplan O; Sterin M; Ruiz-Cabello J; Ash E; Roth Y; Ringel I; Cohen JS
Cancer Res; 2000 Sep; 60(18):5179-86. PubMed ID: 11016646
[TBL] [Abstract][Full Text] [Related]
5. Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence of lonidamine.
Fanciulli M; Bruno T; Giovannelli A; Gentile FP; Di Padova M; Rubiu O; Floridi A
Clin Cancer Res; 2000 Apr; 6(4):1590-7. PubMed ID: 10778993
[TBL] [Abstract][Full Text] [Related]
6. Growth inhibition by rhein and lonidamine of human glioma cells in vitro.
Floridi A; Gentile FP; Bruno T; Castiglione S; Zeuli M; Benassi M
Anticancer Res; 1990; 10(6):1633-6. PubMed ID: 2285235
[TBL] [Abstract][Full Text] [Related]
7. The effect of lonidamine alone and in combination with cisplatin on in vitro growth and viability of lung squamous cell carcinoma cell lines.
Raaphorst GP; Ko D; Feeley MM; Danjoux CE; Maroun J; Evans WK
Anticancer Res; 1991; 11(1):41-7. PubMed ID: 2018379
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of the antineoplastic drug lonidamine: 31P and 13C nuclear magnetic resonance studies.
Ben-Horin H; Tassini M; Vivi A; Navon G; Kaplan O
Cancer Res; 1995 Jul; 55(13):2814-21. PubMed ID: 7796408
[TBL] [Abstract][Full Text] [Related]
9. In vitro potentiation by lonidamine of the sc-RIP saporin 6 effect in a human metastatic breast cancer cell line.
Roncuzzi L; Zoli W; Bajorko P; Gasperi-Campani A
Anticancer Res; 1995; 15(3):773-6. PubMed ID: 7645957
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo potentiation by lonidamine of the antitumor effect of adriamycin.
Zupi G; Greco C; Laudonio N; Benassi M; Silvestrini B; Caputo A
Anticancer Res; 1986; 6(5):1245-9. PubMed ID: 3800331
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of radiation response of prostatic carcinoma by lonidamine.
Dudak SD; Lopez A; Block NL; Lokeshwar BL
Anticancer Res; 1996; 16(6B):3665-71. PubMed ID: 9042239
[TBL] [Abstract][Full Text] [Related]
12. The mode of action of the antitumor agent lonidamine involves calcium-associated actin filament rounding.
Matarrese P; Meschini S; Arancia G; Malorni W
Oncol Rep; 1994 Mar; 1(2):387-92. PubMed ID: 21607371
[TBL] [Abstract][Full Text] [Related]
13. Cytoskeleton as a target in menadione-induced oxidative stress in cultured mammalian cells. I. Biochemical and immunocytochemical features.
Bellomo G; Mirabelli F; Vairetti M; Iosi F; Malorni W
J Cell Physiol; 1990 Apr; 143(1):118-28. PubMed ID: 2318902
[TBL] [Abstract][Full Text] [Related]
14. Morphological effects of lonidamine on two human-tumor cell culture lines.
Szekely JG; Lobreau AU; Delaney S; Raaphorst GP; Feeley M
Scanning Microsc; 1989 Jun; 3(2):681-91; discussion 691-3. PubMed ID: 2814409
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of cisplatin cytotoxicity by lonidamine in primary cultures of human ovarian cancer.
Orlandi L; Zaffaroni N; Gornati D; Veneroni S; Silvestrini R
Anticancer Res; 1994; 14(3A):1161-4. PubMed ID: 8074467
[TBL] [Abstract][Full Text] [Related]
16. PKC mediates 12(S)-HETE-induced cytoskeletal rearrangement in B16a melanoma cells.
Timar J; Tang D; Bazaz R; Haddad MM; Kimler VA; Taylor JD; Honn KV
Cell Motil Cytoskeleton; 1993; 26(1):49-65. PubMed ID: 8221907
[TBL] [Abstract][Full Text] [Related]
17. Lonidamine can enhance the cytotoxic effect of cisplatin in human tumour cells and rodent cells.
Raaphorst GP; Feeley MM; Heller DP; Danjoux CE; Martin L; Maroun JA; De Sanctis AJ
Anticancer Res; 1990; 10(4):923-7. PubMed ID: 2382989
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative activity of 3-aminobenzamide in A431 carcinoma cells is associated with a target effect on cytoskeleton.
Tiozzo R; Monti D; Straface E; Capri M; Croce MA; Rainaldi G; Franceschi C; Malorni W
Biochem Biophys Res Commun; 1996 Aug; 225(3):826-32. PubMed ID: 8780697
[TBL] [Abstract][Full Text] [Related]
19. The in vitro effects of lonidamine combined with cisplatin in human small cell lung cancer cell lines.
Ko D; Raaphorst GP; Feeley MM; Danjoux CE; Maroun JA; Evans WK
Anticancer Res; 1991; 11(1):235-9. PubMed ID: 1850216
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic effect of the association of BCNU with rhein or lonidamine on a human glioma cell line.
Floridi A; Gentile PF; Bruno T; Fanciulli M; Paggi MG; Zeuli M; Benassi M
Anticancer Res; 1991; 11(2):789-92. PubMed ID: 1648334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
